Epitalon

Peptide

Compounding status of Epitalon — FDA 503A bulks-list standing, PCAC review history, and state overlays. Every entry links to the government document it came from.

We do not sell, source, or supply Epitalon. This is a monitoring record from public government sources — not a product, and not advice.

Federal history

Apr 16, 2026PCAC reviewFederal
Under PCAC review
Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
2026-07361 · primary source ↗

State overlays

No state-specific position on Epitalon tracked yet. State boards hold independent authority; legislation is monitored via LegiScan and board positions are added as they are verified.

Track Epitalon changes

Get the free weekly Brief — FDA and state moves on peptide & GLP-1 compounding, with the source and the date. Members get real-time alerts for their states.

Get the free Brief →

← All substances · Informational monitoring from public government sources — not legal or medical advice. No efficacy claims.